Global Epinephrine
Market, by Product Type (Auto-injector, Prefilled Syringes, and Ampoules
and Vials), by Application (Anaphylaxis, Cardiac Arrest, Superficial Bleeding,
Respiratory Disorders, and Others), by Distribution Channel (Hospital Pharmacies,
Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,040
million in 2017, and is projected to exhibit a CAGR of 11.0% over the forecast
period (2018 – 2026), as highlighted in a new report published by.
Significant number of novel
pipeline products to augment the market growth the manufacturers are focused on
developing and commercializing innovative drugs and novel drug delivery systems
of therapeutic molecules to improve patient quality of life and to cater the
clinical shortcomings of the commercially available products. According to the
Mayo Clinic, 2016, more than 200,000 cases of anaphylaxis occur annually in the
U.S., indicating the higher number of potential patient pool in the region.
Also, the World Allergy Organization, in 2015 estimated that up to two percent
of the global population, accounting for 150 million people are expected to
experience anaphylaxis during their lifetime. In July 2018, INSYS Therapeutics,
Inc. demonstrated the results of early clinical trial for its investigational
epinephrine nasal spray, as a potential needle-free, non-invasive, and
easy-to-use alternative to intramuscular injection for the treatment of
anaphylaxis. The investigators also highlighted the benefits of effective
needleless alternative delivery options showing rapid drug absorption. In
August 2018, FDA granted Fast Track designation for the epinephrine nasal
spray. Furthermore, in April 2018, Aquestive Therapeutics initiated the Phase-1
clinical trials for its complex molecule programs- AQST-108 epinephrine
molecule for anaphylaxis, which is administered via sublingual route.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2401
Browse 36 Market Data Tables and
34 Figures spread through 175 Pages and in-depth TOC on “Epinephrine Market”-
Global Forecast to 2026, by Product Type (Auto-injector, Prefilled Syringes,
and Ampoules and Vials), by Application (Anaphylaxis, Cardiac Arrest,
Superficial Bleeding, Respiratory Disorders and Others), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa)
The market players are focused on
strengthening strategic collaborations to provide products freely at retail
outlets, considering shortages in supply of competitors' epinephrine auto-injectors.
For instance, in September 2018, Walgreens and Kaleo entered into partnership
under which AUVI-Q would be available at all pharmacies across the U.S. This
step will aid in increasing accessibility of epinephrine auto-injector. Also,
in July 2018, Adamis Pharmaceuticals announced that Sandoz, a Novartis
division, bought the rights to market its epinephrine device, a pre-filled 0.3
mg-dose syringe called Symjepi in the U.S. market. In 2015, Impax Laboratories,
Inc. acquired Tower Holdings, Inc. including subsidiaries Amedra
Pharmaceuticals LLC. Amedra is manufacturer of the Adrenaclick (epinephrine
injection) auto-injector.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/epinephrine-market-2401
Key Takeaways of the Epinephrine
Market:
The global epinephrine market is
expected to exhibit a CAGR of 11.0% over the forecast period, owing to the
approval of cost-effective generic auto-injectors in the market, and strategic
support of companies and government agencies for increasing generic epinephrine
adoption.
Among product type, auto-injector
segment held a dominant position in the epinephrine market in 2018, owing to
the wide use of the product in auto-injectable form due to ease of
administration and rapid onset of action.
Among application, anaphylaxis
segment held a dominant position in the epinephrine market in 2018, owing to
high incidence rate of anaphylaxis due to consumption of food products such as
peanut or tree nut in children and increasing supplemental new drug application
in infants.
Companies operating in the global
epinephrine market include Mylan N.V., Pfizer, Inc., Teva Pharmaceuticals
Industries Ltd., Impax Laboratories, Inc., Kaleo, Inc., Adamis Pharmaceuticals
Corporation, Bausch Health Companies, ALK- Abello A/S
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2401
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment